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Summary
Chance imbalance in baseline characteristics is common in randomized clinical tri-
als. Regression adjustment such as the analysis of covariance (ANCOVA) is often
used to account for imbalance and increase precision of the treatment effect esti-
mate. An objective alternative is through inverse probability weighting (IPW) of the
propensity scores. Although IPW and ANCOVA are asymptotically equivalent, the
former may demonstrate inferior performance in finite samples. In this article, we
point out that IPW is a special case of the general class of balancing weights, and
advocate to use overlap weighting (OW) for covariate adjustment. The OW method
has a unique advantage of completely removing chance imbalance when the propen-
sity score is estimated by logistic regression. We show that the OW estimator attains
the same semiparametric variance lower bound as the most efficient ANCOVA esti-
mator and the IPW estimator for a continuous outcome, and derive closed-form
variance estimators for OW when estimating additive and ratio estimands. Through
extensive simulations, we demonstrate OW consistently outperforms IPW in finite
samples and improves the efficiency over ANCOVA and augmented IPW when the
degree of treatment effect heterogeneity is moderate or when the outcome model is
incorrectly specified. We apply the proposed OW estimator to the Best Apnea Inter-
ventions for Research (BestAIR) randomized trial to evaluate the effect of continuous
positive airway pressure on patient health outcomes. All the discussed propensity
score weighting methods are implemented in the R package PSweight.
KEYWORDS:
analysis of covariance, covariate balance, inverse probability weighting, overlap weighting, randomized
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1 INTRODUCTION
Randomized controlled trials are the gold standard for evaluating the efficacy and safety of new treatments and interventions.
Statistically, randomization ensures the optimal internal validity and balances both measured and unmeasured confounders in
expectation. This makes the simple unadjusted difference-in-means estimator unbiased for the intervention effect.1 Frequently,
important patient characteristics are collected at baseline; although over repeated experiments, they will be balanced between
treatment arms, chance imbalance often arises in a single trial due to the random nature in allocating the treatment,2,3 especially
when the sample size is limited.4 If any of the baseline covariates are prognostic risk factors that are predictive of the outcome,
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2adjusting for the imbalance of these factors in the analysis can improve the statistical power and provide a greater chance of
identifying the treatment signals when they actually exist.3,5,6
There are two general streams of methods for covariate adjustment in randomized trials: (outcome) regression adjust-
ment7,8,9,10,11 and the inverse probability of treatment weighting (IPW or IPTW) based on propensity scores.12,13,14 For
regression adjustment with continuous outcomes, the analysis of covariance (ANCOVA)model is often used, where the outcome
is regressed on the treatment, covariates and possibly their interactions.10 The treatment effect is estimated by the coefficient
of the treatment variable. With binary outcomes, a generalized linear model can be postulated to estimate the adjusted risk
ratio or odds ratio, with the caveat that the regression coefficient of treatment may not represent the marginal effect due to non-
collapsability.12 Tsiatis and co-authors developed a suite of semiparametric ANCOVA estimators that improves efficiency over
the unadjusted analysis in randomized trials.7,9,10 Lin15 clarified that it is critical to incorporate covariate-by-treatment interac-
tion terms in regression adjustment for efficiency gain. When the randomization probability is 1∕2, ANCOVA returns consistent
point and interval estimates even if the outcome model is misspecified.7,15,16 However, misspecification of the outcome model
can decrease precision in unbalanced experiments with treatment effect heterogeneity.17 Another limitation of regression adjust-
ment is the potential for inviting a ‘fishing expedition’: one may search for an outcome model that gives the most dramatic
treatment effect estimate which jeopardizes the objectivity of causal inference with randomized trials.10,13
Originally developed in the context of survey sampling and observational studies,18 IPW has been advocated as an objec-
tive alternative to ANCOVA in randomized trials.12 To implement IPW, one first fits a logistic working model to estimate the
propensity scores – the conditional probability of receiving the treatment given the baseline covariates,19 and then estimates the
treatment effect by the difference of the weighted outcome – weighted by the inverse of the estimated propensity – between the
treatment arms. In randomized trials, the treatment group is randomly assigned and the true propensity score is known. Therefore,
the working propensity score model is always correctly specified, and the IPW estimator is consistent to the marginal treatment
effect. For a continuous outcome, the IPW estimator with a logistic propensity model has the same large-sample variance as the
efficient ANCOVA estimator,13,12 but it offers the following advantages.
First, IPW separates the design and analysis in the sense that the propensity score model only involves baseline covariates and
the treatment indicator; it does not require the access to the outcome and hence avoids the ‘fishing expedition.’ As such, IPW
offers better transparency and objectivity in pre-specifying the analytical adjustment before outcomes are observed. Second,
IPW preserves the marginal treatment effect estimand with non-continuous outcomes, while the interpretation of the outcome
regression coefficient may change according to different covariate specifications.20,21 Third, IPW can easily obtain treatment
effect estimates for rare binary or categorical outcomes whereas outcome models often fail to converge in such situations.12
This is particularly the case when the target parameter is a risk ratio, where log-binomial models are known to have unsatisfying
convergence properties.22 On the other hand, a major limitation of IPW is that it may be inefficient compared to ANCOVA with
limited sample sizes and unbalanced treatment allocations.23
In this paper, we point out that IPW is a special case of the general class of propensity score weights, called the balancing
weights,24 manymembers of which could be used for covariate adjustment in randomized trials.Within this class, we advocate to
use the overlap weighting (OW).24,25,26,27,28 In the context of randomized trials, a particularly attractive feature of OW is that, if
the propensity score is estimated from a logistic working model, then OW leads to exact mean balance of any baseline covariate
in that model, and consequently remove the chance imbalance of that covariate. As a propensity score method, OW retains
the aforementioned advantages of IPW while offers better finite-sample properties (Section 2). In Section 3, we demonstrate
that the OW estimator, similar as IPW, achieves the same semiparametric variance lower bound and hence is asymptotically
equivalent to the efficient ANCOVA estimator for continuous outcomes. For binary outcomes, we further provide closed-form
variance estimators of the OW estimator for estimating marginal risk difference, risk ratio and odds ratio, which incorporates
the uncertainty in estimating the propensity scores and achieves close to nominal coverage in finite samples. Through extensive
simulations in Section 4, we demonstrate the efficiency advantage of OW under small to moderate sample sizes, and also validate
the proposed variance estimator for OW. Finally, in Section 5 we apply the proposed method to the Best Apnea Interventions
for Research (BestAIR) randomized trial and evaluate the treatment effect of continuous positive airway pressure (CPAP) on
several clinical outcomes.
32 PROPENSITY SCOREWEIGHTING FOR COVARIATE ADJUSTMENT
2.1 The Balancing Weights
We consider a randomized trial with two arms and 푁 patients, where 푁1 and 푁0 patients are randomized into the treatment
and control arm, respectively. Let 푍푖 = 푧 be the binary treatment indicator, with 푧 = 1 indicates treatment and 푧 = 0 control.
Under the potential outcome framework,29 each unit has a pair of potential outcomes {푌푖(1), 푌푖(0)}, mapped to the treatment and
control condition, respectively, of which only the one corresponding to the actual treatment assigned is observed. We denote the
observed outcome as 푌푖 = 푍푖푌푖(1) + (1 −푍푖)푌푖(0). In randomized trials, a collection of 푝 baseline variables could be recorded
for each patient, denoted by 푋푖 = (푋푖1,… , 푋푖푝)푇 . Denote 휇푧 = 퐸{푌푖(푧)} and 휇푧(푥) = 퐸{푌푖(푧)|푋푖 = 푥} as the marginal and
conditional expectation of the outcome in arm 푧 (푧 = 0, 1), respectively. A common estimand on the additive scale is the average
treatment effect (ATE):
휏 = 퐸{푌푖(1) − 푌푖(0)} = 휇1 − 휇0. (1)
We assume that the treatment 푍 is randomly assigned to patients, where Pr(푍푖 = 1|푋푖, 푌푖(1), 푌푖(0)) = Pr(푍푖 = 1) = 푟, and
0 < 푟 < 1 is the randomization probability (seeWeb Appendix A for additional discussions on randomization). The most typical
study design uses balanced assignment with 푟 = 1∕2. Other values of 푟 may be possible, for example, when there is a perceived
benefit of the treatment, and a larger proportion of patients are randomized to the intervention. Under randomization of treatment
and the consistency assumption, we have 휏 = 퐸(푌푖|푍푖 = 1) − 퐸(푌푖|푍푖 = 0), and thus the unadjusted difference-in-means
estimator is:
휏̂UNADJ =
∑푁
푖=1푍푖푌푖∑푁
푖=1푍푖
−
∑푁
푖=1(1 −푍푖)푌푖∑푁
푖=1(1 −푍푖)
. (2)
Below we generalize the ATE to a class of weighted average treatment effect (WATE) estimands to construct alternative
weighting methods. Assume the study sample is drawn from a probability density 푓 (푥), and let 푔(푥) denote the covariate
distribution density of a target population, possibly different from the one represented by the observed sample. The ratio
ℎ(푥) = 푔(푥)∕푓 (푥) is called a tilting function,28 which re-weights the distribution of the baseline characteristics of the study
sample to represent the target population. We can represent the ATE on the target population 푔 by a WATE estimand:
휏ℎ = 퐸푔[푌푖(1) − 푌푖(0)] =
퐸{ℎ(푥)(휇1(푥) − 휇0(푥))}
퐸{ℎ(푥)}
. (3)
In practice, we usually pre-specify ℎ(푥) instead of 푔(푥). Most commonly ℎ(푥) is specified as a function of the propensity score
or simply a constant. The propensity score19 is the conditional probability of treatment given the covariates, 푒(푥) = Pr(푍푖 =
1|푋푖 = 푥). Under the randomization assumption, 푒(푥) = Pr(푍푖 = 1) = 푟 for any baseline covariate value 푥, and therefore as
long as ℎ(푥) is a function of the propensity score 푒(푥), different ℎ corresponds to the same target population 푔, and the WATE
reduces to ATE, i.e. 휏ℎ = 휏. This is distinct from observational studies, where the propensity scores are usually unknown and
vary between units, and consequently different ℎ(푥) corresponds to different target populations and estimands.30 This special
feature under randomized trials provides the basis for considering alternative weighting strategies to achieve better finite-sample
performances.
In the context of confounding adjustment in observational studies, Li et al.24 proposed a class of propensity score weights,
named the balancing weights, to estimateWATE. Specifically, given any ℎ(푥), the balancing weights for patients in the treatment
and control arm are defined as:
푤1(푥) = ℎ(푥)∕푒(푥), 푤0(푥) = ℎ(푥)∕{1 − 푒(푥)}, (4)
which balances the distributions of the covariates between treatment and control arms in the target population, so that
푓1(푥)푤1(푥) = 푓0(푥)푤0(푥) = 푓 (푥)ℎ(푥), where 푓푧(푥) is the conditional distribution of covariates in treatment arm 푧.31,24 Then,
one can use the following Hájek-type estimator to estimate 휏ℎ:
휏̂ℎ = 휇̂ℎ1 − 휇̂
ℎ
0 =
∑푁
푖=1푤1(푥푖)푍푖푌푖∑푁
푖=1푤1(푥푖)푍푖
−
∑푁
푖=1푤0(푥푖)(1 −푍푖)푌푖∑푁
푖=1푤0(푥푖)(1 −푍푖)
. (5)
The function ℎ(푥) can take any form, each corresponding to a specific weighting scheme. For example, when ℎ(푥) = 1, the
balancing weights become the inverse probability weights, (푤1, 푤0) = (1∕푒(푥), 1∕{1 − 푒(푥)}); when ℎ(푥) = 푒(푥)(1 − 푒(푥)), we
have the overlap weights,24 (푤1, 푤0) = (1 − 푒(푥), 푒(푥)), which was also independently developed by Wallace and Moodie31 in
the context of dynamic treatment regimes. Other examples of the balancing weights include the average treatment effect among
treated (ATT) weights32 and the matching weights.33
4IPW is the most well-known case of the balancing weights. Specific to covariate adjustment in randomized trials, Williamson
et al.12 and Shen et al.13 suggested the following IPW estimator of 휏:
휏̂ IPW =
∑푁
푖=1푍푖푌푖∕푒̂푖∑푁
푖=1푍푖∕푒̂푖
−
∑푁
푖=1(1 −푍푖)푌푖∕(1 − 푒̂푖)∑푁
푖=1(1 −푍푖)∕(1 − 푒̂푖)
. (6)
We will point out in Section 3 that their findings on IPW are generally applicable to the balancing weights as long as ℎ(푥) is a
smooth function of the true propensity score. The choice of ℎ(푥), however, will affect the finite-sample operating characteristics
of the weighting estimator. In particular, below we will closely examine the overlap weights.
2.2 The Overlap Weights
In observational studies, the overlap weights correspond to a target population with the most overlap in the baseline character-
istics, and have been shown theoretically to give the smallest asymptotic variance of 휏̂ℎ among all balancing weights24 as well
as empirically reduce the variance of 휏ℎ in finite samples.25 Illustrative examples of the overlap population distribution can be
found in Figure 1 of Li et al.24 with a single covariate as well as in the bubble plot of Thomas et al.34 with two covariates. In
randomized trials, as discussed before, because the true propensity score is constant, the overlap weights and IPW target the
same population estimand 휏, but their finite-sample operating characteristics can be markedly different, as elucidated below.
The OW estimator for the ATE in randomized trials is
휏̂OW = 휇̂1 − 휇̂0 =
∑푁
푖=1(1 − 푒̂푖)푍푖푌푖∑푁
푖=1(1 − 푒̂푖)푍푖
−
∑푁
푖=1 푒̂푖(1 −푍푖)푌푖∑푁
푖=1 푒̂푖(1 −푍푖)
, (7)
where 푒̂푖 = 푒(푋푖; 휃̂) is the estimated propensity score from a working logistic regression model:
푒푖 = 푒(푋푖; 휃) =
exp(휃0 +푋푇푖 휃1)
1 + exp(휃0 +푋푇푖 휃1)
, (8)
with parameters 휃 = (휃0, 휃푇1 )푇 and 휃̂ is the maximum likelihood estimate of 휃. Regarding the selection of covariates in thepropensity score model, the previous literature suggests to include stratification variables as well as a small number of key
prognostic factors pre-specified in the design stage.35,12 These guidelines are also applicable to the OW estimator.
The logistic propensity score model fit underpins a unique exact balance property of OW. Specifically, the overlap weights
estimated from model (8) lead to exact mean balance of any predictor included in the model (Theorem 3 in Li et al.24):∑푁
푖=1(1 − 푒̂푖)푍푖푋푗푖∑푁
푖=1(1 − 푒̂푖)푍푖
−
∑푁
푖=1 푒̂푖(1 −푍푖)푋푗푖∑푁
푖=1 푒̂푖(1 −푍푖)
= 0, for 푗 = 1, ..., 푝. (9)
This property has important practical implications in randomized trials, namely, for any baseline covariate included in the
propensity score model, the associated chance imbalance in a single randomized trial vanishes once the overlap weights are
applied. If one reports the weighted mean differences in baseline covariates between arms (frequently included in the standard
“Table 1" in primary trial reports), those differences are identically zero. Thus the application of OW enhances the face validity
of the randomized study.
More importantly, the exact mean balance property translates into better efficiency in estimating 휏. To illustrate the intuition,
consider the following simple example. Suppose the true outcome surface is 푌푖 = 훼 +푍푖휏 +푋푇푖 훽0 + 휀푖 with 퐸(휀푖|푍푖, 푋푖) = 0.Denote the weighted chance imbalance in the baseline covariates by
Δ푋(푤0, 푤1) =
∑푁
푖=1푤1(푋푖)푍푖푋푖∑푁
푖=1푤1(푋푖)푍푖
−
∑푁
푖=1푤0(푋푖)(1 −푍푖)푋푖∑푁
푖=1푤0(푋푖)(1 −푍푖)
,
and the weighted difference in random noise by
Δ휀(푤0, 푤1) =
∑푁
푖=1푤1(푋푖)푍푖휀푖∑푁
푖=1푤1(푋푖)푍푖
−
∑푁
푖=1푤0(푋푖)(1 −푍푖)휀푖∑푁
푖=1푤0(푋푖)(1 −푍푖)
.
For the unadjusted estimator, substituting the true outcome surface in equation (2) gives 휏̂UNADJ−휏 = Δ푋(1, 1)푇 훽0+Δ휀(1, 1).This
expression implies that the estimation error of 휏̂UNADJ is a sum of the chance imbalance and random noise, and becomes large when
imbalanced covariates are highly prognostic (i.e. large magnitude of 훽0). Similarly, if we substitute the true outcome surface in
5(6), we can show that the estimation error of IPW is 휏̂ IPW − 휏 = Δ푋(1∕(1 − 푒̂), 1∕푒̂)푇 훽0 + Δ휀(1∕(1 − 푒̂), 1∕푒̂). Intuitively, IPW
controls for chance imbalance because we usually have ‖Δ푋(1∕(1 − 푒̂), 1∕푒̂)‖ < ‖Δ푋(1, 1)‖, which reduces the variation of
the estimation error over repeated experiments. However, because Δ푋(1∕(1 − 푒̂), 1∕푒̂) is not zero, the estimation error remains
sensitive to the magnitude of 훽0. In contrast, because of the exact mean balance property of OW, we have Δ푋(푒̂, 1 − 푒̂) = 0;
consequently, substituting the true outcome surface in (7), we can see that the estimation error of OWequals 휏̂OW−휏 = Δ휀(푒̂, 1−푒̂),
which is only noise and free of 훽0. This simple example illustrates that, for each realized randomization, OW should have the
smallest estimation error, which translates into larger efficiency in estimating 휏 over repeated experiments.
For non-continuous outcomes, we also consider ratio estimands. For example, while the ATE is also known as the causal risk
difference with binary outcomes, 휏 = 휏RD. Two other standard estimands are the causal risk ratio (RR) and the causal odds ratio
(OR) on the log scale, defined by
휏RR = log
(
휇1
휇0
)
, 휏OR = log
{
휇1∕(1 − 휇1)
휇0∕(1 − 휇0)
}
. (10)
The OW estimator for risk ratio and odds ratio are 휏̂RR = log{휇̂1∕휇̂0}, and 휏̂OR = log{휇̂1∕(1 − 휇̂1)}∕{휇̂0∕(1 − 휇̂0)}, respectively,
with 휇̂1, 휇̂0 defined in (7).
3 EFFICIENCY CONSIDERATIONS AND VARIANCE ESTIMATION
In this section we demonstrate that in randomized trials the OWestimator leads to increased large-sample efficiency in estimating
the treatment effect compared to the unadjusted estimator. We further propose a consistent variance estimator for the OW
estimator of both the additive and ratio estimands.
3.1 Continuous Outcomes
Tsiatis et al.10 show that the family of regular and asymptotically linear estimators for the additive estimand 휏 is
 ∶ 1
푁
푁∑
푖=1
{
푍푖푌푖
푟
−
(1 −푍푖)푌푖
1 − 푟
−
푍푖 − 푟
푟(1 − 푟)
{
푟푔0(푋푖) + (1 − 푟)푔1(푋푖)
}}
+ 표푝(푁−1∕2), (11)
where 푟 is the randomization probability, and 푔0(푋푖), 푔1(푋푖) are scalar functions of the baseline covariates 푋푖. Several com-
monly used estimators for the treatment effect are members of the family , with different specifications of 푔0(푋푖), 푔1(푋푖). For
example, setting 푔0(푋푖) = 푔1(푋푖) = 0, we obtain the unadjusted estimator 휏̂UNADJ. Setting 푔0(푋푖) = 푔1(푋푖) = 퐸(푌푖|푋푖), we obtain
the “ANCOVA I” estimator in Yang and Tsiatis,7 which is the least-squares solution of the coefficient of푍푖 in a linear regression
of 푌푖 on 푍푖 and 푋푖. Further, setting 푔0(푋푖) = 퐸(푌푖|푍푖 = 0, 푋푖) and 푔1(푋푖) = 퐸(푌푖|푍푖 = 1, 푋푖), we obtain the “ANCOVA II”
estimator,7,10,15 which is the least-squares solution of the coefficient of 푍푖 in a linear regression of 푌푖 on 푍푖, 푋푖 and their inter-
action terms. This estimator achieves the semiparametric variance lower bound within the family , when the conditional mean
functions 푔0(푋푖) and 푔1(푋푖) are correctly specified in the ANCOVA model.36,9 Another member of  is the target maximum
likelihood estimator,37,38,14 which is asymptotic efficient under correct outcome model specification. The IPW estimator 휏̂ IPW is
also a member of . Specifically, Shen et al.13 showed that if the logistic model (8) is used to estimate the propensity score 푒̂푖,
then the IPW estimator is asymptotically equivalent to the “ANCOVA II" estimator and becomes semiparametric efficient if the
true 푔0(푋푖) and 푔1(푋푖) are linear functions of 푋푖.
In the following Proposition we show that the OW estimator is also a member of  and is asymptotically efficient under the
linearity assumption. The proof of Proposition 1 is provided in Web Appendix A.
Proposition 1. (Asymptotic efficiency of overlap weighting)
(a) If the propensity score is estimated by a parametric model 푒(푋; 휃) with parameters 휃 that satisfies a set of mild regularity
conditions (specified in Web Appendix A), then 휏̂OW belongs to the class of estimators .
(b) Suppose 푋1 and 푋2 are two nested sets of baseline covariates with 푋2 = (푋1, 푋∗1), and 푒(푋1; 휃1), 푒(푋2; 휃2) are nested
smooth parametric models. Write 휏̂OW1 and 휏̂OW2 as two OW estimators with the weights defined through 푒(푋1; 휃̂1) and 푒(푋2; 휃̂2),respectively. Then the asymptotic variance of 휏̂OW2 is no larger than that of 휏̂OW1 .(c) If the propensity score is estimated from the logistic regression (8), then 휏̂OW is asymptotically equivalent to the “ANCOVA
II" estimator, and becomes semiparametric efficient as long as the true 퐸(푌푖|푋푖, 푍푖 = 1) and 퐸(푌푖|푋푖, 푍푖 = 0) are linear in 푋푖.
6Proposition 1 summarizes the large-sample properties of the OWestimator in randomized trials, extending those demonstrated
for IPW in Shen et al.13 In particular, adjusting for the baseline covariates using OW does not adversely affect efficiency in large
samples than without adjustment. Further, the asymptotic equivalence between 휏̂OW and the “ANCOVA II" estimator indicates
that OW becomes fully semiparametric efficient when the conditional outcome surface is a linear function of the covariates
adjusted in the logistic propensity score model. In the special case where the randomization probability 푟 = 1∕2, we show in
Web Appendix B that the limit of the large-sample variance of 휏̂OW is
lim
푁→∞
푁Var(휏̂OW) = (1 −푅2푌̃∼푋) lim푁→∞푁Var(휏̂
UNADJ) = 4(1 −푅2푌̃∼푋)Var(푌̃푖), (12)
where 푌̃푖 = 푍푖(푌푖−휇1)+(1−푍푖)(푌푖−휇0) is the mean-centered outcome and푅2푌̃∼푋 measures the proportion of explained varianceafter regressing 푌̃푖 on 푋푖. Similar definition of 푅-squared was also used elsewhere when demonstrating efficiency gain with
covariate adjustment.37,38,16 The amount of variance reduction is also a direct result from the asymptotic equivalence between
the OW, IPW, and “ANCOVA II” estimators. Equation (12) shows that incorporating additional covariates into the propensity
score model will not reduce the asymptotic efficiency because 푅2
푌̃∼푋
is non-decreasing when more covariates are considered.
Although adding covariates does not hurt the asymptotic efficiency, in practice we recommend incorporating the covariates that
exhibit baseline imbalance and that have large predictive power for the outcome.12
Perhaps more interestingly, the results in Proposition 1 apply more broadly to the family of balancing weights estimators,
formalized in the following Proposition. The proof of Proposition 2 is presented in Web Appendix A.
Proposition 2. (Extension to balancing weights)
Proposition 1 holds for the general family of estimators (5) using balancing weights defined in (4), as long as the tilting function
ℎ(푋) is a “smooth” function of the propensity score, where “smooth” is defined by satisfying a set of mild regularity conditions
(specified in details in Web Appendix A).
3.2 Binary Outcomes
For binary outcomes, the target estimand could be the causal risk difference, risk ratio and odds ratio, denoted as 휏RD, 휏RR and
휏OR, respectively. The discussions in Section 3.1 directly apply to the estimation of the additive estimand, 휏RD. When estimating
the ratio estimands, one should proceed with caution in interpreting regression parameters for the ANCOVA-type generalized
linear models due to the potential non-collapsibility issue. Additionally, it is well-known that the log-binomial model frequently
fails to converge with a number of covariates, and therefore one may have to resort to less efficient regression methods such as
the modified Poisson regression.22 Williamson et al.12 showed that IPW can be used to adjust for baseline covariates without
changing the interpretation of the marginal treatment effect estimands, 휏RR and 휏OR. Because of the asymptotic equivalence
between the IPW and OW estimators (Proposition 1), OW shares the advantages of IPW in improving the asymptotic efficiency
over the unadjusted estimators for risk ratio and odds ratio without compromising the interpretation of the marginal estimands.
In addition, due to its ability to remove all chance imbalance associated with푋푖, OW is likely to give higher efficiency than IPW
in finite samples, which we will demonstrate in Section 4.
3.3 Variance Estimation
To estimate the variance of the propensity score estimators, it is important to incorporate the uncertainty in estimating the
propensity scores.18 Failing to do so leads to conservative variance estimates of the weighting estimator and therefore reduces
power of the Wald test for treatment effect.12 Below we use the M-estimation theory39 to derive a consistent variance estimator
for OW. Specifically, we cast 휇̂1, 휇̂0 in equation (7), and 휃̂ in the logistic model (8) as the solutions 휆̂ = (휇̂1, 휇̂0, 휃̂푇 )푇 to the
following joint estimation equations∑푁푖=1 푈푖 = ∑푁푖=1 푈 (푌푖, 푋푖, 푍푖; 휆̂) = 0, where
푛∑
푖=1
푈 (푌푖, 푋푖, 푍푖, 휆) =
푁∑
푖=1
⎡⎢⎢⎣
푍푖(푌푖 − 휇1)(1 − 푒푖)
(1 −푍푖)(푌푖 − 휇0)푒푖
푋̃푖(푍푖 − 푒푖)
⎤⎥⎥⎦ = 0, (13)
where 푋̃푖 = (1, 푋푇푖 )푇 is the augmented covariates with an intercept. Here, the first two rows represent the estimating functionsfor 휇̂1 and 휇̂0 and the last rows are the score functions of the logistic model with an intercept and main effects of푋푖. If푋푖 is of 푝
dimensions, equation (13) involves 푝+3 scalar estimating equations for 푝+3 parameters. Let퐴 = −퐸(휕푈푖∕휕휆)푇 ,퐵 = 퐸(푈푖푈푇푖 ),the asymptotic covariance matrix for 휆̂ can be written as 푁−1퐴−1퐵퐴−푇 . Extracting the covariance matrix for the first two
7components in 휆̂, we can show that, as푁 goes to infinity,√
푁
[
휇̂1 − 휇1
휇̂0 − 휇0
]
→
{
0,
[
Σ11,Σ12
Σ21,Σ22
]}
, (14)
where the covariance matrix is defined as the corresponding elements in 퐴−1퐵퐴−푇 ,
Σ11 = [퐴−1퐵퐴−푇 ]1,1,Σ22 = [퐴−1퐵퐴−푇 ]2,2,Σ12 = Σ푇21 = [퐴
−1퐵퐴−푇 ]1,2. (15)
where [퐴−1퐵퐴−푇 ]푗,푘 denotes the (푗, 푘)th element of the matrix퐴−1퐵퐴−푇 . Using the delta method, we can obtain the asymptotic
variance of 휏̂OWRD , 휏̂OWRR , 휏̂OWOR as a function of Σ11,Σ22,Σ12. Consistent plug-in estimators can then be obtained by estimating theexpectations in the “sandwich”matrix퐴−1퐵퐴−푇 by their corresponding sample averages.We summarize the variance estimators
for 휏̂OWRD , 휏̂OWRR , 휏̂OWOR in the following general equations,
Var(휏̂OW) = 1
푁
⎡⎢⎢⎣푉̂ UNADJ − 푣̂푇1
{
1
푁
푁∑
푖=1
푒̂푖(1 − 푒̂푖)푋̃푇푖 푋̃푖
}−1
(2푣̂1 − 푣̂2)
⎤⎥⎥⎦ , (16)
where
푉̂ UNADJ =
{
1
푁
푁∑
푖=1
푒̂푖(1 − 푒̂푖)
}−1(
퐸̂21
푁1
푁∑
푖=1
푍푖푒̂푖(1 − 푒̂푖)2(푌푖 − 휇̂1)2 +
퐸̂20
푁0
푁∑
푖=1
(1 −푍푖)푒̂2푖 (1 − 푒̂푖)(푌푖 − 휇̂0)
2
)
,
푣̂1 =
{
1
푁
푁∑
푖=1
푒̂푖(1 − 푒̂푖)
}−1(
퐸̂1
푁1
푁∑
푖=1
푍푖푒̂
2
푖 (1 − 푒̂푖)(푌푖 − 휇̂1)
2푋̃푖 +
퐸̂0
푁0
푁∑
푖=1
(1 −푍푖)푒̂푖(1 − 푒̂푖)2(푌푖 − 휇̂0)2푋̃푖
)
,
푣̂2 =
{
1
푁
푁∑
푖=1
푒̂푖(1 − 푒̂푖)
}−1(
퐸̂1
푁1
푁∑
푖=1
푍푖푒̂푖(1 − 푒̂푖)2(푌푖 − 휇̂1)2푋̃푖 +
퐸̂0
푁0
푁∑
푖=1
(1 −푍푖)푒̂2푖 (1 − 푒̂푖)(푌푖 − 휇̂0)
2푋̃푖
)
,
and 퐸̂푘 depends on the choice of estimands. For 휏̂OWRD , we have 퐸̂푘 = 1; for 휏̂OWRR , we set 퐸̂푘 = 휇̂−1푘 ; for 휏̂OWOR , we use 퐸̂푘 =
휇̂−1푘 (1 − 휇̂푘)
−1 with 푘 = 0, 1. Detailed derivation of the asymptotic variance and its consistent estimator can be found in Web
Appendix B. These variance calculations are implemented in the R package PSweight.40
4 SIMULATION STUDIES
We carry out extensive simulations to investigate the finite-sample operating characteristics of OW relative to IPW, direct regres-
sion adjustment and an augmented estimator that combined IPW and outcome regression. The main purpose of the simulation
study is to empirically (i) illustrate that OW leads to marked finite-sample efficiency gain compared with IPW in estimating the
treatment effect, and (ii) validate the sandwich variance estimator of OW developed in Section 3.3. Below we focus on the sim-
ulations with continuous outcomes. We have also conducted extensive simulations with binary outcomes, the details of which
are presented in Web Appendix D.
4.1 Simulation Design
We generate 푝 = 10 baseline covariates from the standard normal distribution, 푋푖푗∼ (0, 1), 푗 = 1, 2,⋯ , 푝. Fixing the ran-
domization probability 푟, the treatment indicator is randomly generated from a Bernoulli distribution, 푍푖 ∼ Bern(푟). Given the
baseline covariates 푋푖 = (푋푖1,… , 푋푖푝)푇 , we generate the potential outcomes from the following linear model (model 1): for
푧 = 0, 1,
푌푖(푧)∼ (푧훼 +푋푇푖 훽0 + 푧푋푇푖 훽1, 휎2푦 ), 푖 = 1, 2,⋯ , 푁 (17)
where 훼 is the main effect of the treatment, and 훽0, 훽1 are the effects of the covariates and treatment-by-covariate interactions.
The observed outcome is set to be 푌푖 = 푌푖(푍푖) = 푍푖푌푖(1) + (1 −푍푖)푌푖(0). In our data generating process, because the baseline
covariates have mean zero, the true average treatment effect on the additive scale 휏 = 훼. For simplicity, we fix 휏 = 0 and
choose 훽0 = 푏0 × (1, 1, 2, 2, 4, 4, 8, 8, 16, 16)푇 , 훽1 = 푏1 × (1, 1, 1, 1, 1, 1, 1, 1, 1, 1)푇 . We specify the residual variance 휎2푦 = 2,
8and choose the multiplication factor 푏0 so that the signal-to-noise ratio (due to the main effects) is 1, namely, ∑푝푖=1 훽20푖∕휎2푦 = 1.This specification mimics a scenario where the baseline covariates can explain up to 50% of the variation in the outcome. We
also assign different importance to each covariates. For example, the last two covariates, 푋9, 푋10, explain the majority of the
variation, mimicking the scenario that one may have access to only a few strong prognostic risk factors. We additionally vary
the value of 푏1 ∈ {0, 0.25, 0.5, 0.75} to control the strength of treatment-by-covariate interactions. A larger value of 푏1 indicates
a higher level of treatment effect heterogeneity so that the baseline covariates are more strongly associated with the individual-
level treatment contrast, 푌푖(1) − 푌푖(0). For brevity, we present the results with 푏1 = 0.25, 0.5 to the Web Appendix and focus
here on the scenarios with homogeneous treatment effect (푏1 = 0) and with the strongest effect heterogeneity (푏1 = 0.75). For
the randomization probability 푟, we consider two values: 푟 = 0.5 represents a balanced design with one-to-one randomization,
and 푟 = 0.7 an unbalanced assignment where more patients are randomized to the treatment arm. We also vary the total sample
sizes푁 from 50 to 500, with 50 and 500 mimicking a small and large sample scenario, respectively.
In each simulation scenario, we compare several different estimators for ATE, including the unadjusted estimator 휏̂UNADJ
(UNADJ), the IPW estimator 휏̂ IPW, the estimator based on linear regression 휏̂LR (LR), and the OW estimator 휏̂OW. For the IPW
and OW estimators, we estimate the propensity score by logistic regression including all baseline covariates as linear terms,
and the final estimator is given by the Hájek-type estimator (5) using the corresponding weights. For the LR estimator, we fit
the correctly specified outcome model (17) (model 1). In addition, we also consider an augmented IPW (AIPW) estimator that
augments IPW with an outcome regression,18 which is also a member of the class :
휏̂AIPW = 휇̂AIPW1 − 휇̂
AIPW
0 =
1
푁
푁∑
푖=1
{
푍푖푌푖
푒̂푖
−
(푍푖 − 푒̂푖)휇̂1(푋푖)
푒̂푖
}
−
{ (1 −푍푖)푌푖
1 − 푒̂푖
+
(푍푖 − 푒̂푖)휇̂0(푋푖)
1 − 푒̂푖
}
, (18)
where 휇̂푧(푋푖) = 퐸̂[푌푖|푋푖, 푍푖 = 푧] is the prediction from the outcome regression. In the context of observational studies, such
an estimator is also known as the doubly-robust estimator. Because AIPW hybrids propensity score weighting and outcome
regression, it does not retain the objectivity of the former. Nonetheless, the AIPW estimator is often perceived as an improved
version of IPW41; therefore, we also compare it in the simulations to understand its operating characteristics in randomized trials.
For each scenario, we simulate 2000 replicates, and calculate the bias, Monte Carlo variance and mean squared error for each
estimator of 휏. Across all scenarios, as expected we find that the bias of all estimators is negligible, and thus the Monte Carlo
variance and the mean squared error are almost identical. For this reason, we focus on reporting the efficiency comparisons
using the Monte Carlo variance. We define the relative efficiency of an estimator as the ratio between the Monte Carlo variance
of that estimator and that of the unadjusted estimator. Relative efficiency larger than one indicates that estimator is more efficient
than the unadjusted estimator. We also examine the empirical coverage rate of the associated 95% normality-based confidence
intervals. Specifically, the confidence interval of 휏̂LR, 휏̂ IPW, and 휏̂OW is constructed based on the Huber-White estimator in Lin,15
the sandwich estimator inWilliamson et al.,12 and the sandwich estimator developed in Section 3.3, respectively. The confidence
interval of 휏̂AIPW is the based on the sandwich variance derived based on the M-estimation theory; the details are presented in
Web Appendix C.
To explore the performance of the estimators under model misspecification, we repeat the simulations by replacing the
potential outcome generating process with the following model (model 2)
푌푖(푧)∼ (푧훼 +푋푇푖 훽0 + 푧푋푇푖 훽1 +푋푇푖,int훾, 휎2푦 ), (19)
where푋푖,int = (푋푖1푋푖2, 푋푖2푋푖3,⋯ , 푋푖푝−1푋푖푝) represents 푝−1 interactions between pairs of covariates with consecutive indices
and 훾 =
√
휎2푦∕푝 × (1, 1,⋯ , 1)
푇 represents the strength of this interaction effect. The LR estimator omitting these additional
interactions is thus considered as misspecified. For IPW and OW, the propensity score model is technically correctly specified
(because the true randomization probability is a constant) even though it does not adjust for the interaction term 푋푖,int. The
AIPW estimator similarly omits푋푖,int in both the propensity score and outcome models. With a slight abuse of terminology, we
refer to this scenario as “model misspecification."
4.2 Results on Efficiency of Point Estimators
Figure 1 presents the relative efficiency of the different estimators in four typical scenarios. For a more clear presentation, we
omit the results for 휏̂AIPW as they become indistinguishable from the results for 휏̂LR in these scenarios. Below, we discuss in order
the relative efficiency results when the outcomes are generated under model 1 (panel (a) to (c)) and model 2 (panel (d)).
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FIGURE 1 The relative efficiency of 휏̂ IPW, 휏̂AIPW, 휏̂LR and 휏̂OW relative to 휏̂UNADJ for estimating ATE when (a) 푟 = 0.5, 푏1 = 0 and
the outcome model is correctly specified, (b) 푟 = 0.5, 푏1 = 0.75 and the outcome model is correctly specified, (c) 푟 = 0.7, 푏1 = 0
and the outcome model is correctly specified, (d) 푟 = 0.7, 푏1 = 0 and the outcome model is misspecified. A larger value of
relative efficiency corresponds to a more efficient estimator.
Panel (a) to (c) correspond to scenarios when the outcomes are simulated from model 1. When 푟 = 0.5 and there is no
treatment effect heterogeneity (panel (a)), it is evident that 휏̂ IPW, 휏̂LR, and 휏̂OW are consistently more efficient than the unadjusted
estimator, and the relative efficiency increases with a larger sample size. However, when the sample size is no larger than 100,
OW leads to higher efficiency compared to LR and IPW, with IPW being the least efficient among the adjusted estimators. With
a strong treatment effect heterogeneity 푏1 = 0.75 (panel (b)), 휏̂LR becomes slightly more efficient than 휏̂OW; this is expected as
the true outcome model is used and the design is balanced. The efficiency advantage decreases for 휏̂LR and as 푏1 moves closer
to zero (see Web Table 1). On the other hand, 휏̂OW becomes more efficient than 휏̂LR when the randomization probability deviates
from 0.5. For instance, in panel (c), with 푟 = 0.7 and 푁 = 50, 휏̂LR becomes even less efficient than the unadjusted estimator,
while OW demonstrates substantial efficiency gain over the unadjusted estimator. The deteriorating performance of 휏̂LR under
푟 = 0.7 also supports the findings in Freedman.17 These results show that the relative performance between LR and OW is
affected by the degree of treatment effect heterogeneity and the randomization probability. In the scenarios with a small degree
of effect heterogeneity and/or with unbalanced design, OW tends to be more efficient than LR.
Overall, OW is generally comparable to LR with a correctly specified outcome model, both outperforming IPW. But OW
becomes more efficient than LR when the outcome model is incorrectly specified. Namely, when the outcomes are generated
frommodel 2, 휏̂OW becomes the most efficient even if the propensity model omits important interaction terms in the true outcome
model, as in panel (d) of Figure 1. The fact that LR and AIPW have almost identical finite-sample efficiency further confirms that
the regression component dominates the AIPW estimator in randomized trials. Throughout, 휏̂OW is consistently more efficient
than 휏̂ IPW, regardless of sample size, randomization probability and the degree of treatment effect heterogeneity.When the sample
size increases to 푁 = 500, the differences between methods become smaller as a result of Proposition 1. Additional results on
relative efficiency are also provided in Table 1 and Web Appendix Table 1.
4.3 Results on Variance and Interval Estimators
Table 1 summarizes the accuracy of the estimated variance and the empirical coverage rate of each interval estimator in four
scenarios that match Figure 1. The former is measured by the ratio between the average estimated variance and the Monte Carlo
variance of each estimator, and a ratio close to 1 indicates adequate performance. In general, we find that estimated variance
is close to the truth for both IPW and OW, but less so for the LR and AIPW estimator, especially with small sample sizes
such as 푁 = 50 or 100. Specifically, when the outcomes are generated from model 1, the sandwich variances of IPW and OW
estimators usually adequately quantify the uncertainty, even when the sample size is as small as 푁 = 50. In the same settings,
the Huber-White variance estimator for LR sometimes substantially underestimates the true variance, leading to under-coverage
of the interval estimator. Also, in the case where LR has a slight efficiency advantage (푏1 = 0.75), the coverage of LR is only
around 70% even when the true linear regression model is estimated. This result shows that the Huber-White sandwich variance,
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although known to be robust to heteroscedasticity in large samples, could be severely biased towards zero in finite samples when
there is treatment effect heterogeneity. Further, the sandwich variance of AIPW also frequently underestimates the true variance
when 푁 = 50 and 100. On the other hand, when the outcomes are generated from model 2 and the randomization probability
is 푟 = 0.7, all variance estimators tend to underestimate the truth, and the coverage rate slightly deteriorates. However, the
coverage of the IPW and OW estimators is still closer to nominal than LR and AIPW when푁 = 50 and 100.
TABLE1 The relative efficiency of each estimator compared to the unadjusted estimator, the ratio between the average estimated
variance over Monte Carlo variance ({Est Var}/{MC Var}), and 95% coverage rate of IPW, LR, AIPW and OW estimators. The
results are based on 2000 simulations with a continuous outcome. In the “correct specification" scenario, data are generated from
model 1; in the "misspecification" scenario, data are generated from model 2. For each estimator, the same analysis approach is
used throughout, regardless of the data generating model.
Sample size Relative efficiency {Est Var}/{MC Var} 95% Coverage
푁 IPW LR AIPW OW IPW LR AIPW OW IPW LR AIPW OW
푟 = 0.5, 푏1 = 0, correct specification
50 1.621 2.126 2.042 2.451 1.001 0.866 0.668 1.343 0.936 0.933 0.885 0.967
100 2.238 2.475 2.399 2.548 0.898 0.961 0.799 1.116 0.938 0.944 0.914 0.955
200 2.927 2.987 2.984 3.007 0.951 0.996 0.927 1.051 0.946 0.949 0.938 0.956
500 2.985 3.004 2.995 3.006 0.963 0.987 0.959 1.000 0.944 0.949 0.942 0.952
푟 = 0.5, 푏1 = 0.75, correct specification
50 1.715 3.043 2.972 2.570 0.991 0.286 0.816 1.383 0.935 0.712 0.918 0.967
100 2.679 3.279 3.253 3.003 0.931 0.280 0.917 1.168 0.942 0.710 0.934 0.966
200 2.979 3.220 3.215 3.023 0.967 0.278 0.995 1.075 0.951 0.697 0.949 0.964
500 3.337 3.425 3.426 3.338 0.995 0.273 1.013 1.037 0.943 0.696 0.945 0.954
푟 = 0.7, 푏1 = 0, correct specification
50 1.056 0.036 0.036 2.270 1.060 0.014 0.026 1.184 0.938 0.779 0.816 0.931
100 1.825 2.439 2.311 2.935 0.914 0.858 0.717 1.039 0.946 0.921 0.897 0.923
200 2.474 2.706 2.679 2.874 0.971 0.931 0.857 0.963 0.948 0.944 0.927 0.935
500 2.641 2.743 2.738 2.809 0.922 0.912 0.887 0.925 0.940 0.936 0.934 0.938
푟 = 0.7, 푏1 = 0, misspecification
50 0.896 0.009 0.009 1.468 0.843 0.005 0.009 0.857 0.904 0.777 0.808 0.906
100 1.096 1.258 1.152 1.533 0.724 0.754 0.637 0.837 0.911 0.903 0.878 0.917
200 1.390 1.457 1.398 1.570 0.861 0.894 0.816 0.898 0.929 0.938 0.920 0.933
500 1.591 1.632 1.612 1.648 0.980 1.003 0.976 0.981 0.948 0.949 0.948 0.949
4.4 Simulation Studies with Binary Outcomes
We also perform a set of simulations with binary outcomes, generating from a logistic outcome model. Three estimands, 휏RD, 휏RR
and 휏OR, are considered in scenarios with different degree of treatment effect heterogeneity, prevalence of the outcome Pr(푌푖 = 1),
and randomization probability 푟. In these scenarios, we find that covariate adjustment improves efficiency of the unadjusted
estimator most likely when the sample size is at least 100, except under large treatment effect heterogeneity where there is
efficiency gain even with 푁 = 50. Throughout, the OW estimator is uniformly more efficient than IPW and should be the
preferred propensity score weighting estimator in randomized trials. Finally, although the correctly-specified outcome regression
is slightly more efficient than OW in the ideal case with a non-rare outcome, in small samples regression adjustment is generally
unstable when the prevalence of outcome also decreases. Similarly, the efficiency of AIPW is mainly driven by the outcome
regression component, and the instability of the outcomemodel may also lead to an inefficient AIPW estimator in finite-samples.
For brevity, we present full details of the simulation design in Web Appendix D, and summarize all numerical results in Web
Table 2 and 3.
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5 APPLICATION TO THE BEST APNEA INTERVENTIONS FOR RESEARCH TRIAL
The Best Apnea Interventions for Research (BestAIR) trial is an individually-randomized, parallel-group trial designed to
evaluate the effect of continuous positive airway pressure (CPAP) treatment on the health outcomes of patients with high cardio-
vascular disease risk and obstructive sleep apnea but without severe sleepiness.42 Patients were recruited from outpaient clinics
at three medical centers in Boston, Massachusetts, and were randomized in a 1:1:1:1 ratio to receive conservative medical ther-
apy (CMT), CMT plus sham CPAP (sham CPAP is a modified device that closely mimics the active CPAP and serves as the
placebo for CPAP RCTs43), CMT plus CPAP, or CMT plus CPAP plus motivational enhancement (ME). We follow the study
protocol and pool two sub-arms into the combined control group (CMT, CMT plus sham CPAP) and the rest sub-arms into the
combined CPAP or active intervention group. This results in 169 participants with 83 patients in the active CPAP group and 86
patients in the combined control arm. A set of patient-level covariates were measured at baseline and outcomes were measured
at baseline, 6, and 12 months.
For illustration, we consider estimating the treatment effect of CPAP on two outcomes measured at 6 month. The objective
outcome is the 24-hour systolic blood pressure (SBP), measured every 20 minutes during the daytime and every 30 minutes
during the sleep. The subjective outcome includes the self-reported sleepiness in daytime, measured by Epworth Sleepiness
Scale (ESS).44 We additionally consider dichotomizing SBP (high SBP if ≥130mmHg) to create a binary outcome, resistant
hypertension. For covariate-adjusted analysis, we consider a total of 9 baseline covariates, including demographics (e.g. age,
gender, ethnicity), body mass index, Apnea-Hypopnea Index (AHI), average seated radial pulse rate (SDP), site and baseline
outcome measures (e.g. baseline blood pressure and ESS).
In Table 2, we provide the summary statistics for the covariates and compare between the treated and control groups at baseline.
We measure the baseline imbalance of the covariates by the absolute standardized difference (ASD), which for the 푗th covariate
is defined as, ASD푤 = |∑푁푖=1푤푖푋푖푗푍푖∕∑푁푖=1푤푖푍푖−∑푁푖=1푤푖푋푖푗(1−푍푖)∕∑푁푖=1푤푖(1−푍푖)|∕푆푗 , where푤푖 represents the weightfor each patient and 푆2푗 stands for the average variance, 푆2푗 = {Var(푋푖푗|푍푖 = 1) +Var(푋푖푗|푍푖 = 0)}∕2. The baseline imbalanceis measured by ASDUNADJ with 푤푖 = 1. Although the treatment is randomized, we still notice a considerable difference for some
covariates between the treated and control group, such as BMI, baseline SBP and AHI. The ASDUNADJ for all three variables
exceed 10%, which has been considered as a common threshold for balance.45 In particular, the baseline SBP exhibits the largest
imbalance (ASDUNADJ = 0.477), and is expected to be highly correlated with SBP measured at 6 months, the main outcome of
interest. As we shall see later, failing to adjust for such a covariate leads to spurious conclusions of the treatment effect. Using
the propensity scores estimated from a main-effects logistic model, IPW reduces the baseline imbalance as ASDIPW < 10%.
As expected from the exact balance property (equation (9)), OW completely remove baseline imbalance such that ASDOW = 0
for all covariates. In this regard, even before observing the 6-month outcome, applying OW mitigates the severe imbalance on
prognostic baseline factors, and thus increases the face validity of the trial.
For the continuous outcomes (SBP and ESS), we estimate the ATE using 휏̂UNADJ, 휏̂ IPW, 휏̂AIPW, 휏̂LR and 휏̂OW. For IPW and OW, we
estimate the propensity scores using a logistic regression with main effects of 9 baseline covariates mentioned above. For 휏̂LR,
we fit the ANCOVA model with main effects of treatment and covariates as well as their interactions. For the binary SBP, we
use these five approaches to estimate the causal risk difference, log risk ratio and log odds ratio due to the CPAP treatment. For
휏̂LR with a binary outcome, we fit a logistic regression model for the outcome including both main effects of the treatment and
covariates, as well as their interactions, and then obtain the marginal mean of each group via standardization. For each outcome,
the corresponding propensity score and outcome model specifications are used to obtain the AIPW estimator. The variances and
95% CIs of the estimators are calculated in the same way as in the simulations. We present p-values for the associated hypothesis
tests of no treatment effect and occasionally interpret statistical significance at the 0.05 level for illustrative purposes. We do
acknowledge, however, that the interpretation of study results should not rely on a single dichotomy of a p-value that is great
than or smaller than 0.05.
Table 3 presents the treatment effect estimates, standard errors (SEs), 95% confidence intervals (CI) and p-values for these
five approaches across three outcomes. For the SBP continuous outcome, the treatment effect estimated by IPW, LR, AIPW and
OW are substantially smaller than the unadjusted estimate. Specially, the ATE changes from approximately −5.0 to −2.7 after
covariate adjustment. This difference is due to the fact that the control group has a higher average SBP at baseline and failing
to adjust for this discrepancy leads to a biased estimate of the treatment effect of CPAP. In fact, one would falsely conclude
a statistically significant treatment effect at the 0.05 level if the baseline imbalance is ignored. The treatment effect becomes
no longer statistically significant at the 0.05 level using either one of the adjusted estimator. In terms of efficiency, IPW, LR,
AIPW and OW provide a smaller SE compared with the unadjusted estimate and the difference among the adjusted estimators
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TABLE 2 Baseline characteristics of the BestAIR randomized trial by treatment groups, and absolute standardized difference
(ASD) between the treatment and control groups before and after weighting. The ASDOW is exactly zero due to the exact balance
property of OW.
All patients CPAP group Control group ASDUNADJ ASDIPW ASDOW
푁 = 169 푁1 = 83 푁0 = 86
Baseline categorical covariates and number of units in each group.
Gender (male) 107 54 53 0.046 0.002 0.000
Race & ethnicity
White 152 75 77 0.051 0.015 0.000
Black 11 5 6 0.060 0.007 0.000
Other 5 2 3 0.086 0.034 0.000
Recruiting center
Site 1 54 26 28 0.046 0.002 0.000
Site 2 10 5 5 0.065 0.024 0.000
Site 3 105 52 53 0.073 0.013 0.000
Baseline continuous covarites, mean and standard deviation (in parenthesis).
Age (years) 64.4 (7.4) 64.4 (8.0) 64.3 (6.8) 0.020 0.017 0.000
BMI (kg/m2) 31.7 (6.0) 31.0 (5.3) 32.4 (6.5) 0.261 0.042 0.000
Baseline SBP (mmHg) 124.3 (13.2) 121.6 (11.1) 127.0 (14.6) 0.477 0.020 0.000
Baseline SDP (beats/minute) 63.1 (10.7) 63.0 (10.4) 63.2 (10.9) 0.020 0.016 0.000
Baseline AHI (events/hr) 28.8 (15.4) 26.5 (13.0) 31.1 (17.2) 0.348 0.039 0.000
Baseline ESS 8.3 (4.5) 8.0 (4.5) 8.5 (4.6) 0.092 0.010 0.000
is negligible. For the ESS outcome, the treatment effect estimate changes from approximately −1.5 to −1.25 after covariate
adjustment while the difference among IPW, LR, AIPW and OW remains small. Despite the change in the point estimates, the
95% confidence intervals for all five estimators exclude the null.
For the binary SBP outcome, the unadjusted method gives an estimate of −0.224 on risk difference scale, −0.698 on log
risk ratio scale and −1.038 on log odds ratio scale. Due to baseline imbalance, the unadjusted confidence intervals for all three
estimands exclude null. Similar to the analysis of the continuous SBP outcome, all four adjusted approaches move the point
estimates closer to the null. This pattern further demonstrates that ignoring baseline imbalance may produce biased estimates.
In terms of variance reduction, all four adjusted methods exhibit a decrease in the estimated standard error compared with the
unadjusted one. Interestingly, although the 95% confidence intervals for LR, AIPW and OW all include zero, the confidence
intervals for IPW excludes zero for the two ratio estimands (but not for the additive estimand). This result, however, needs to
be interpreted with caution. As noticed in the simulation studies (panel (b), (c) and (d) in Web Figure 1), variance estimators of
IPW and AIPW tend to underestimate the actual uncertainty when the sample size is modest and the outcome is not common.
In our application, the resistant hypertension has a prevalence of around 12%, which is close to the most extreme scenario in our
simulation. Because IPW likely underestimates the variability for ratio estimands, there could be a risk of inflated type I error.
In contrast, the interval estimator of OW appears more robust in small samples.
6 DISCUSSION
We advocate to use the overlap propensity score weighting (OW) method for covariate adjustment in randomized clinical tri-
als. Compared with the regression adjustment approach, the propensity score approach encourages pre-planned adjustments of
baseline covariates, and promote objectivity and transparency in the design and analysis of randomized trials. We have demon-
strated that the OW estimator is asymptotically equivalent to the IPW and ANCOVA estimators, which becomes semiparametric
efficient when the true outcome surface is linear in the covariates.
Through extensive simulation studies, we find the OW estimator is consistently more efficient than the IPW estimator in finite
samples, particularly when the sample size is small (e.g. smaller than 150). This is largely due to the exact balance property
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TABLE 3 Treatment effect estimates of CPAP intervention on blood pressure, day time sleepiness and resistant hypertension
using data from the BestAIR study. The five approaches considered are: (a) UNADJ: the unadjusted estimator; (b) IPW: inverse
probability weighting; (c) LR: linear regression (for continous outcomes, or ANCOVA) and logistic regression (for binary
outcomes) for outcome; (d) AIPW: augmented IPW; (e) OW: overlap weighting.
Method Estimate Standard error 95% Confidence interval p-value
Continuous outcomes
Systolic blood pressure (continuous)
UNADJ −5.070 2.345 (−9.667,−0.473) 0.031
IPW −2.638 1.634 (−5.841, 0.566) 0.107
LR −2.790 1.724 (−6.169, 0.588) 0.106
AIPW −2.839 1.642 (−6.058, 0.380) 0.084
OW −2.777 1.689 (−6.088, 0.534) 0.100
Epworth Sleepiness Scale (continuous)
UNADJ −1.503 0.702 (−2.878,−0.128) 0.032
IPW −1.232 0.486 (−2.184,−0.279) 0.011
LR −1.260 0.519 (−2.276,−0.243) 0.015
AIPW −1.255 0.479 (−2.193,−0.317) 0.009
OW −1.251 0.491 (−2.214,−0.288) 0.011
Binary outcomes
Resistant hypertension (SBP≥130): risk difference
UNADJ −0.224 0.085 (−0.391,−0.057) 0.009
IPW −0.145 0.082 (−0.306, 0.015) 0.077
LR −0.131 0.074 (−0.277, 0.014) 0.076
AIPW −0.133 0.071 (−0.272, 0.006) 0.061
OW −0.149 0.083 (−0.312, 0.013) 0.071
Resistant hypertension (SBP≥130): log risk ratio
UNADJ −0.698 0.281 (−1.248,−0.147) 0.013
IPW −0.448 0.226 (−0.892,−0.004) 0.048
LR −0.401 0.236 (−0.864, 0.062) 0.090
AIPW −0.408 0.227 (−0.854, 0.037) 0.072
OW −0.454 0.263 (−0.970, 0.062) 0.084
Resistant hypertension (SBP≥130): log odds ratio
UNADJ −1.038 0.409 (−1.838,−0.237) 0.011
IPW −0.665 0.324 (−1.300,−0.030) 0.040
LR −0.598 0.346 (−1.276, 0.080) 0.084
AIPW −0.607 0.331 (−1.256, 0.041) 0.067
OW −0.680 0.387 (−1.438, 0.079) 0.079
that is unique to OW, which removes all chance imbalance in the baseline covariates adjusted for in a logistic propensity model.
Our simulations also shed light on the performance of the regression adjustment method. With a continuous outcome, linear
regression adjustment have similar efficiency to the OW and IPW estimators when the sample size is more than 150. With
a limited sample size, say 푁 ≤ 150, the linear regression estimator is occasionally slightly more efficient than OW when
correctly specified, while the OW estimator is more efficient when the linear model is incorrectly specified. We find that when
the sample size is smaller than 100, linear regression adjustment could even be less efficient than the unadjusted estimators
when (i) the randomization probability deviates from 0.5, and/or (ii) the outcome model is incorrectly specified. In contrast,
the OW estimator consistently leads to finite-sample efficiency gain over the unadjusted estimator in these scenarios. Although
we generally believe the sample size is a major determining factor for efficiency comparison, our cutoff of 푁 at 100 or 150
is specific to our simulation setting, and may not be generalizable to other scenarios we haven’t considered. The findings for
binary outcomes are slightly different from those for the continuous outcomes, especially in small samples (Web Appendix D).
In particular, OW generally performs similarly to the logistic regression estimator, and both approaches may lead to efficiency
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loss over the unadjusted estimator when the sample size is limited, e.g., 푁 < 100. However, the efficiency loss generally does
not exceed 10%. Throughout, the IPW estimator is the least efficient and could lead to over 20% efficiency loss compared to
the unadjusted estimator in small samples. The findings for estimating the risk ratio and odds ratio are mostly concordant with
those for estimating the risk difference. Of note, when the binary outcome is rare, regression adjustment frequently run into
convergence issues and fails to provide an adjusted treatment effect, while the propensity score weighting estimators are not
subject to such problems. Finally, because previous simulations37,38,14 with binary outcomes have focused on trials with at least
a sample size of푁 = 200, our simulations complement those previous reports by providing recommendations when the sample
size falls below 200.
We also empirically evaluated the finite-sample performance of the AIPW estimator in randomized trials. The AIPW estimator
is popular in observational studies due to its double robustness and local efficiency properties. In randomized trials, because the
propensity score model is never misspecified, the finite-sample performance of AIPW is largely driven by the outcome model. In
particular, we find that AIPW can be less efficient than the unadjusted estimator under outcome model misspecification (Table
1). The sensitivity of AIPW to the outcome model specification was noted previously.46,47 AIPW could be slightly more efficient
than OWwith a correct outcome model and under substantial treatment effect heterogeneity, but it does not retain the objectivity
of the simple weighting estimator and is subject to excessive variance when the outcome model is incorrect or fails to converge.
We further provide a consistent variance estimator for OWwhen estimating both additive and ratio estimands. Our simulation
results confirm that the resulting OW interval estimator achieved close to nominal coverage for the additive estimand (ATE),
except in a few challenging scenarios where the sample size is extremely small, e.g. 푁 = 50. For example, with a continuous
outcome, the empirical coverage of the OW interval estimator and the IPW interval estimator12 are both around 90% when
the randomization is unbalanced and the propensity score model does not account for important covariate interaction terms. In
this case, the Huber-White variance for linear regression has the worst performance and barely achieved 80% coverage. This
is in sharp contrast to the findings of Raad et al.,23 who have demonstrated superior coverage of the linear regression interval
estimator over the IPW interval estimator. However, Raad et al.23 only considered the model-based variance (i.e. based on the
information matrix) when the outcome regression is correctly specified. Assuming a correct model specification, it is expected
that the model-based variance has more stable performance than the Huber-White variance in small samples, while the former
may become biased under incorrect model specification when the randomization probability deviates from 0.5 .16 For robustness
and practical considerations, we therefore focused on studying the operating characteristics of the commonly recommended
Huber-White variance.15 On the other hand, the OW interval estimator maintains at worst over-coverage for estimating the risk
ratios and odds ratios when 푁 = 50, while the IPW interval estimator exhibits under-coverage. When the outcome is rare,
the logistic regression and AIPW interval estimators show severe under-coverage possibly due to constant non-convergence.
Collectively, these results indicate the potential type I error inflation by using IPW, logistic regression and AIPW, and could
favor the application of OW for covariate adjustment in trials with a limited sample size.
OW is easy to implement in practice. For applied researchers who are familiar with IPW, the switch to OWonly involves a one-
line change of the programming code: changing the weights from the reciprocal of the estimated probability of being assigned
to the observed arm (IPW) to the probability of being assigned to the opposite arm (OW). Though the variance estimation is
more complex, we have provided reproducible R code with implementation details in Web Appendix E and our GitHub page:
https://github.com/zengshx777/OWRCT_codes_package. Alternatively, OW, IPW and AIPW estimators are implemented in
our recent R package PSweight,40 available on CRAN at https://CRAN.R-project.org/package=PSweight.
There are a number of possible extensions of the proposed method. First, subgroup analysis is routinely conducted in ran-
domized trials to examine whether the treatment effect depends on certain sets of patient characteristics.48 For the same reason
of transparency, it would be natural to develop propensity score weighting estimators for subgroup-specific treatment effects.49
Because the sample size of each subgroup may be limited, it is of particular interest to study whether OW is also effective in
improving the efficiency in this context. Second, multi-arm randomized trials are common and the interest usually lies in deter-
mining the pairwise average treatment effect.50 Although the basic principle of improving efficiency via covariate adjustment
still applies, there is a lack of empirical evaluation as to which adjustment approach works better in finite samples. In particular,
the performance of multi-group ANCOVA and propensity score weighting merits further study. In the context of observational
studies, we have previously extended OW to multiple treatments,28 which is potentially applicable to multi-arm randomized tri-
als. Third, although we have examined the AIPW estimator that combines IPW and direct regression, it remains to be explored
whether an alternative hybrid estimator combining OW and outcome regression can lead to further improvement.51 Lastly,
covariate adjustment is also relevant in cluster randomized controlled trials, where entire clusters of patients (such as hospitals
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or clinics) are randomized to intervention conditions.52 Due to a limited number of clusters available in such studies, design-
based adjustment for baseline characteristics are often considered by covariate-constrained randomization,53,54 in which case
regression-based adjustment in the analysis stage is necessary not only for maintaining the type I error rate but also for effi-
ciency improvement.55 It remains an open question whether OW could similarly improve the performance of IPW for addressing
challenges in the analysis of cluster randomized trials.
APPENDIX
Web appendix is available at our GitHub page: https://github.com/zengshx777/OWRCT_codes_package.
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